September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Ocular Manifestations of HIV at Boston Medical Center: A 15 Year Retrospective Study
Author Affiliations & Notes
  • Erol Eri Verter
    Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States
  • Lisa Rice
    Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States
  • Nicole Siegel
    Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Erol Verter, None; Lisa Rice, None; Nicole Siegel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2055. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Erol Eri Verter, Lisa Rice, Nicole Siegel; Ocular Manifestations of HIV at Boston Medical Center: A 15 Year Retrospective Study. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2055.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : CDC estimated that 1.2 million people aged 13 and older in the USA were infected with HIV in 2012. Despite the advent of HAART in 1996 and the drastically changing ocular manifestations of HIV, ophthalmologists should still remain aware of common ocular finding of HIV for early diagnosis of HIV and management of its ocular symptoms.

Methods : In this IRB-approved retrospective study, we catalogued the ocular manifestations of HIV patients at BMC between January 2000 and May 2015. By utilizing our electronic medical records and the billing code for HIV, we recruited subjects who visited our ophthalmology department after their HIV diagnosis. Among this pool, we searched for related billing codes for known ocular diseases associated with HIV. CD4 counts, viral loads and documented compliance with HAART, were recorded by reviewing the infectious disease physicians’ notes within three months of the diagnosis of the ocular finding.

Results : A total of 1239 patients were identified, 59% male and 41% female. The racial demographics included 61% African American, 15% Caucasian, 5% Hispanic and 19% defined as other. The most common associated diagnoses were iridocylitis NOS (5.5%), chorioretinitis NOS (5.2%) and retinal hemorrhages (2.3%). At the time of ocular diagnosis, 75% of subjects had CD4 counts less than 500 cells/mm. However, as expected, 78% of patients with CMV retinitis had CD4 counts less than 200 at the time of diagnosis versus 37% overall (p=0.01). According to the ID notes, 56% were compliant with HAART. Compared to the pre-HAART era, CMV retinitis rates decreased from 30-40% to 1.6% (p=0.001) after the introduction of HAART therapy. Of those with CMV retinitis only 18% were compliant with HAART (p= 0.03). The rates of HZO dropped significantly from 5% in the pre-HAART era to 1.4% (p=0.02) after the advent of HAART, with 83% of patients having CD4 counts less than 500 and 62% deemed non-compliant with HAART.

Conclusions : Our study implicates the declining nature of ocular manifestations of HIV since the advent of HAART, as well as revisits the changing paradigm of HIV related ocular diseases. We do however realize possible under diagnosis due to billing code bias, patient noncompliance, as well as visits to outside institutions.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×